We are proud to be part of Clover Biopharmaceuticals’ important achievement in advancing innovative respiratory combination vaccines.
VisMederi contributed to the RSV+hMPV±PIV3 Combination Vaccines Phase I study by performing serological analyses, supporting the generation of key data that demonstrate the potential of Clover’s next-generation vaccine candidates.
These positive preliminary results represent a meaningful step toward addressing unmet needs in respiratory disease prevention, including broader protection beyond RSV alone.
This collaboration reflects our continuous commitment to scientific excellence and to working with global partners who share the same vision-developing innovative tools to improve public health worldwide.
